Michael Barbella, Managing Editor03.05.22
Products were in the spotlight this past week on MPO's website.
Cybervisitors accessed the page to learn more about a drug-eluting contact lens, a urinary incontinence solution, and miniaturized auto injector technology. Clinical data on home dialysis and aFib treatment also drove traffic.
The drug-eluting contact lens came from Johnson & Johnson Vision Care, which received FDA approval for its ACUVUE Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen). Each lens contains 19 micrograms of the antihistamine ketotifen to relieve allergy-causing itchy eyes. The daily disposable lenses are designed to prevent ocular itch from allergic conjunctivitis and correct vision for those without red eyes who do not have more than 1.00 D of astigmatism.
Another FDA-approved product garnering interest was Valencia Technologies Corporation's eCoin leadless tibial neurostimulator to treat urinary urge incontinence (UUI), a condition that affects more than 60 percent of overactive bladder sufferers. The company claims it is the first tibial nerve stimulator implant approved by the FDA. The eCoin nickel-sized stimulator is implanted subcutaneously above the ankle over the tibial nerve in a minimally invasive outpatient procedure. It contains a primary battery and once programmed, automatically delivers intermitten stimulation to the tibial nerve, helping to reduce UUI symptoms.
BlackHägen won patent approval for a miniaturized auto injector technology that permits different volumetric capabilities ranging from 25 mm3 to 2,500 mm3. These smaller devices are easier to carry and can be seamlessly integrated with other platforms such as robotics, microsurgery tools and endoscopes, telemedicine IoT, and veterinary applications.
Data released by Baxter and Boston Scientific racked up page views as well this past week. Baxter released new data from a 1,500-patient study showing use of its Sharesource remote patient management with an automated peritoneal dialysis cycler can improve home kidney care's clinical efficacy by extending time on therapy by 3.4 months. Boston Scientific, meanwhile, totuted results from its SURPASS trial showing a 0.37 percent major adverse event rate with the WATCHMAN FLX left appendage closure device.
1. FDA Approves J&J Vision's ACUVUE Theravision Drug-Eluting Contact Lenses
2. BlackHägen Design Receives Patent Approval for Innovative Auto-Injector Design
3. Baxter's Sharesource Boosts Time on Home Dialysis by Over 3 Months
4. Valencia's eCoin for Urinary Urge Incontinence Gains FDA PMA
BlackHägen
Cybervisitors accessed the page to learn more about a drug-eluting contact lens, a urinary incontinence solution, and miniaturized auto injector technology. Clinical data on home dialysis and aFib treatment also drove traffic.
The drug-eluting contact lens came from Johnson & Johnson Vision Care, which received FDA approval for its ACUVUE Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen). Each lens contains 19 micrograms of the antihistamine ketotifen to relieve allergy-causing itchy eyes. The daily disposable lenses are designed to prevent ocular itch from allergic conjunctivitis and correct vision for those without red eyes who do not have more than 1.00 D of astigmatism.
Another FDA-approved product garnering interest was Valencia Technologies Corporation's eCoin leadless tibial neurostimulator to treat urinary urge incontinence (UUI), a condition that affects more than 60 percent of overactive bladder sufferers. The company claims it is the first tibial nerve stimulator implant approved by the FDA. The eCoin nickel-sized stimulator is implanted subcutaneously above the ankle over the tibial nerve in a minimally invasive outpatient procedure. It contains a primary battery and once programmed, automatically delivers intermitten stimulation to the tibial nerve, helping to reduce UUI symptoms.
BlackHägen won patent approval for a miniaturized auto injector technology that permits different volumetric capabilities ranging from 25 mm3 to 2,500 mm3. These smaller devices are easier to carry and can be seamlessly integrated with other platforms such as robotics, microsurgery tools and endoscopes, telemedicine IoT, and veterinary applications.
Data released by Baxter and Boston Scientific racked up page views as well this past week. Baxter released new data from a 1,500-patient study showing use of its Sharesource remote patient management with an automated peritoneal dialysis cycler can improve home kidney care's clinical efficacy by extending time on therapy by 3.4 months. Boston Scientific, meanwhile, totuted results from its SURPASS trial showing a 0.37 percent major adverse event rate with the WATCHMAN FLX left appendage closure device.
1. FDA Approves J&J Vision's ACUVUE Theravision Drug-Eluting Contact Lenses
2. BlackHägen Design Receives Patent Approval for Innovative Auto-Injector Design
3. Baxter's Sharesource Boosts Time on Home Dialysis by Over 3 Months
4. Valencia's eCoin for Urinary Urge Incontinence Gains FDA PMA
5. Boston Scientific Releases WATCHMAN FLX Real-World Data
BlackHägen